<DOC>
	<DOCNO>NCT00004197</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Vaccines may make body build immune response kill cancer cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial vaccine therapy plus sargramostim follow chemotherapy treat patient previously untreated aggressive non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy Plus Sargramostim Following Chemotherapy Treating Patients With Previously Untreated Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine ability recombinant idiotype immunotherapy stimulate specific immune response B cell idiotype malignant clone constitutes tumor patient previously untreated aggressive non-Hodgkin 's lymphoma . II . Determine safety toxicity treatment regimen use Genitope Corporation 's molecular rescue technology patient population . OUTLINE : Patients receive induction chemotherapy consist cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) cyclophosphamide , mitoxantrone , vincristine , prednisone ( CNOP ) . Treatment repeat every 3 week maximal clinical response achieve follow 2 additional course consolidation therapy maximum 6 course . At 2-6 month follow completion chemotherapy , patient achieve adequate disease response receive vaccination consist recombinant tumor derive immunoglobulin idiotype keyhole limpet hemocyanin conjugate subcutaneously ( SQ ) follow sargramostim ( GM-CSF ) SQ , 2 separate site day 1 . Patients receive GM-CSF alone day 2-4 . Vaccination repeat every 4 week 4 dos , follow 3 month later fifth final dose . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter disease progression . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma Diffuse mix cell Diffuse large cell Immunoblastic Follicular large cell 50 % large cell Mantle cell Nonage adjust International Prognostic Index 24 Tumor sample safely accessible biopsy , needle aspiration , phlebotomy Must adequate circulate lymphoma cell No CNS metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : WBC great 2,500/mm3 Platelet count great 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 2.0 mg/dL SGOT/SGPT le 2 time normal Renal : Creatinine le 2.0 mg/dL Other : No illness condition , include innate pharmacologic immunosuppression , would preclude study No malignancy within last 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy lymphoma Chemotherapy : No prior cytotoxic chemotherapy lymphoma Endocrine therapy : No prior steroid lymphoma At least 2 month since prior nonphysiologic dos prednisone great 20 mg equivalent No concurrent maintenance steroid great 5mg daily prednisone equivalent Radiotherapy : No prior radiotherapy lymphoma Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>